PURACYP
The World Leader In Transcriptional Analysis of ADMET Genes
Assessing gene transcription as an endpoint for determining induction of drug metabolizing enzymes and transporters has become the “method of choice” in the FDA’s latest draft Guidance for Industry drug interaction studies.
Increased gene transcription due to NCE exposure can be determined by two distinct methods; nuclear receptor activation, and changes in mRNA levels in primary cultures.
Puracyp has become THE “gene transcription company” by providing both of these services. Our newest products meet the regulatory challenges associated with induction guidelines.
Our Advantages
- Employing reporter genes governed by the P450 promoters allows for accurate gene activation from the ligand-activated receptor. Correlations between binding affinity and activation are more readily predicted.
- When ligands bind to the full-length receptor they can produce conformational alterations that influence the extent of gene transcription. Our competitors employ only the ligand binding domain (LBD) of the receptor.
- Low variability and high reproducibility with results comparable to those obtained in primary cultures. Simple and easy to perform, with completion in 24 to 48 hours. Indirect NR activators can be identified. Indirect activators cannot be detected with mammalian two-hybrid or ligand binding assays.
- Puracyp is the only nuclear receptor (NR) company that has functional assays allowing agonists to be differentiated from antagonist. Our competitors assays only determine binding to the LBD. These assays cannot identify agonism vs antagonism.